Advertisement
Screener

Spruce Biosciences, Inc. (SPRB) Graph

SPRB Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Revenue (m); Research and development $12.16M; Operating expenses $16.51M; Net income -$16.23M.
  • 2026-03-31: Revenue (m); Research and development $7.58M; Operating expenses $11.99M; Net income -$12.27M.
  • 2025-12-31: Revenue $0.00*; Research and development $4.10M*; Operating expenses $11.10M*; Net income -$14.65M*.
  • 2025-09-30: Revenue $0.00; Research and development $5.01M; Operating expenses $8.23M; Net income -$8.21M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentOperating expensesNet income
2026-06-30(m)$12.16M$16.51M-$16.23M
2026-03-31(m)$7.58M$11.99M-$12.27M
2025-12-31$0.00*$4.10M*$11.10M*-$14.65M*
2025-09-30$0.00$5.01M$8.23M-$8.21M
2025-06-30$0.00-$430.00K$2.69M-$2.07M
2025-03-31$0.00$10.84M$14.49M-$14.04M
2024-09-30$602.00K$6.55M$10.01M-$8.67M
2024-06-30$1.61M$8.09M$11.65M-$9.18M
2024-03-31$2.00M$10.32M$14.63M-$11.63M
2023-09-30$3.07M$13.49M$16.73M-$12.35M
2023-06-30$2.17M$13.13M$16.14M-$12.82M
2023-03-31$1.96M$11.71M$15.16M-$12.79M
2022-09-30$0.00$8.79M$11.56M-$11.40M
2022-06-30$0.00$9.06M$11.88M-$11.87M
2022-03-31$0.00$8.51M$11.73M-$11.76M
2021-09-30(m)$8.61M$11.40M-$11.45M
2021-06-30(m)$9.12M$11.71M-$11.77M
2021-03-31(m)$6.71M$9.82M-$9.89M
2020-09-30(m)$7.77M$9.56M-$9.59M
2020-06-30(m)$5.66M$6.39M-$6.45M
2020-03-31(m)$4.61M$5.13M-$5.17M
2019-09-30(m)$2.11M$2.56M-$2.55M
2019-06-30(m)(m)(m)-$3.24M
2019-03-31(m)(m)(m)-$4.12M

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesNet income
2026-06-30(m)$19.74M$28.50M-$28.50M
2025-06-30$0.00$10.41M$17.18M-$16.11M
2024-06-30$3.61M$18.41M$26.28M-$20.81M
2023-06-30$4.13M$24.84M$31.30M-$25.61M
2022-06-30$0.00$17.57M$23.62M-$23.64M
2021-06-30(m)$15.83M$21.53M-$21.66M
2020-06-30(m)$10.27M$11.52M-$11.61M

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesNet income
2025-09-30$0.00$15.42M$25.41M-$24.32M
2024-09-30$4.21M$24.96M$36.29M-$29.48M
2023-09-30$7.20M$38.33M$48.03M-$37.97M
2022-09-30$0.00$26.36M$35.17M-$35.04M
2021-09-30(m)$24.44M$32.93M-$33.11M
2020-09-30(m)$18.04M$21.08M-$21.20M
2019-09-30(m)$7.97M$9.97M-$9.91M

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$0.00$19.52M$36.51M$0.00-$38.97M
2024-12-31$4.91M$46.42M$61.06M$0.00-$53.04M
2023-12-31$10.09M$49.43M$62.08M$0.00-$47.92M
2022-12-31$0.00$35.20M$47.28M$0.00-$46.18M
2021-12-31(m)$30.70M$42.07M$0.00-$42.29M
2020-12-31(m)$23.85M$29.42M$0.00-$29.54M
2019-12-31(m)$10.82M$13.11M$0.00-$13.09M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Korro Bio, Inc. (KRRO)United States$0.141B-1.81
Atrium Therapeutics, Inc. (RNA)United States$0.140B
Corbus Pharmaceuticals Holdings, Inc. (CRBP)United States$0.144B-1.72
Curanex Pharmaceuticals Inc (CURX)United States$0.138B
Annexon, Inc. (ANNX)United States$0.147B-4.22
TuHURA Biosciences, Inc./NV (HURA)United States$0.134B-4.88
Unicycive Therapeutics, Inc. (UNCY)United States$0.134B-3.70
NRX Pharmaceuticals, Inc. (NRXP)United States$0.131B-6.31
MEDICINOVA INC (MNOV)United States$0.130B-6.04
IMMUNIC, INC. (IMUX)United States$0.127B-1.88